Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD - HCPLive

Dietary potassium restriction is important for managing hyperkalemia, or high blood potassium levels, in individuals on maintenance hemodialysis, but it imposes a substantial day-to-day burden. Results from a recent clinical trial indicate that adding the potassium binder sodium zirconium cyclosilicate (SZC) may help. The findings will be presented at ASN Kidney Week 2026 October 22–25. In the multicenter, randomized, open-label, parallel-group trial, outpatients receiving thrice-weekly maintenance hemodialysis with pre-dialysis serum potassium of 5.5 to <6.5 mEq/L were assigned to SZC plus standardized nutritional counseling or nutritional counseling alone for 8 weeks.

Amphetamine-associated rhabdomyolysis is an uncommon but potentially life-threatening condition. Massive release of myoglobin and intracellular electrolytes may result in severe metabolic, cardiovascular, and renal complications, particularly acute kidney injury (AKI). We report two cases of severe amphetamine-associated rhabdomyolysis complicated by dialysis-requiring AKI. The first patient, a 46-year-old man, presented with a serum creatine kinase (CK) level of 947,699 U/L, serum creatinine of 734 µmol/L, hyperkalemia of 6.8 mmol/L, and transient left ventricular systolic dysfunction. Management consisted of supportive therapy and eleven sessions of intermittent hemodialysis. The clinical course was complicated by severe delayed hypercalcemia (4.10 mmol/L), followed by cardiac arrest and death. The second patient, a 42-year-old man, presented with a serum CK level of 525,796 U/L, serum creatinine of 544 µmol/L, and hyperkalemia of 7.5 mmol/L. He received supportive treatment and ten sessions of intermittent hemodialysis, resulting in near-complete recovery of renal function. Urine toxicology screening was positive for amphetamines in both patients. Alternative traumatic and non-t

Amphetamine-associated rhabdomyolysis is an uncommon but potentially life-threatening condition. Massive release of myoglobin and intracellular electrolytes may result in severe metabolic, cardiovascular, and renal complications, particularly acute kidney injury (AKI). We report two cases of severe amphetamine-associated rhabdomyolysis complicated by dialysis-requiring AKI. The first patient, a 46-year-old man, presented with a serum creatine kinase (CK) level of 947,699 U/L, serum creatinine of 734 µmol/L, hyperkalemia of 6.8 mmol/L, and transient left ventricular systolic dysfunction. Management consisted of supportive therapy and eleven sessions of intermittent hemodialysis. The clinical course was complicated by severe delayed hypercalcemia (4.10 mmol/L), followed by cardiac arrest and death. The second patient, a 42-year-old man, presented with a serum CK level of 525,796 U/L, serum creatinine of 544 µmol/L, and hyperkalemia of 7.5 mmol/L. He received supportive treatment and ten sessions of intermittent hemodialysis, resulting in near-complete recovery of renal function. Urine toxicology screening was positive for amphetamines in both patients. Alternative traumatic and non-t

First-of-its-kind national analysis yields insights that could inform disaster and emergency planning In the midst of another intense wildfire season, a new study sheds light on the risks they pose to life-sustaining dialysis care for thousands of Canadians.